Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

NCT00273910 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

104

Enrollment

NIH

Sponsor class

Conditions

High-Risk Melanoma

Interventions

DRUG: gp100:209-217 (210M)
DRUG: Montanide ISA-51
DRUG: Imiquimod

Sponsor

National Cancer Institute (NCI)